Europe's drug regulator has found a possible link between the Oxford/AstraZeneca's Covid-19 vaccine and rare blood clotting issues in adults who had received the shot and said it had taken into consideration all currently available evidence.
The European Medicines Agency has said the "benefit-risk remains positive" for the Oxford/AstraZeneca Covid-19 vaccine. The EMA said blood clots should be listed as a "very rare" side effect of the AstraZeneca coronavirus vaccine but that the jab's benefits continue to outweigh the risks. "EMA's safety committee has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects" of the shot, the Amsterdam-based EU drug regulator said in a statement. "OneRead more on rte.ie